Record quarterly revenue of
PMA supplement for second-generation LungFit PH system remains under FDA review; transport capability expected to drive greater market penetration, pending approval
Reaffirms revenue guidance of
Conference call today at
“Building on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval,” said
Recent Financial and Operating Highlights
- Reported revenue of
$2.3 million for the quarter endedSeptember 30, 2026 , the highest quarterly revenue in the Company’s history, representing approximately 28% growth over the same period last year and 31% growth compared with the quarter endedJune 30, 2026 . - Executed the Company’s enhanced commercial strategy for first-generation LungFit PH, supporting increased adoption of its cylinder-free nitric oxide technology.
- Advanced preparations for the potential
U.S . commercial launch of the second-generation LungFit PH system, subject to FDA approval. If approved, the Company believes the addition of transport capability would enableBeyond Air to serve as a single-source nitric oxide provider for hospitals and health systems. - Received FDA Breakthrough Device Designation for LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD). The Company does not plan to allocate resources to further development of LungFit GO until the commercial launch of second-generation LungFit PH is well established, following FDA approval.
- Announced a definitive agreement under which
UNIVO Pharmaceutical Industries Ltd. would acquire the Company’s controlling interest inNeuroNOS Israel Ltd. The transaction is intended to provide NeuroNOS with dedicated resources, funding and strategic focus to advance its development programs. - Evaluating potential development partnerships and other strategic arrangements to support the continued advancement of Beyond Cancer’s pipeline, while maintaining Beyond Air’s focus and resource allocation on its commercialization of LungFit PH.
Pending Regulatory Milestones
- The PMA supplement for the second-generation LungFit PH system, submitted in
June 2025 , remains under FDA review.
Financial Results for the Quarter Ended
Revenue for the quarter ended
Research and development expenses for the three months ended
Selling, general and administrative expenses for the three months ended
Other expense for the three months ended
Net loss attributed to common stockholders of
As of
Financial Guidance
The Company reaffirms its previously issued revenue guidance of
Conference Call and Webcast
Domestic: 1-877-407-0784
International: 1-201-689-8560
Conference ID: 13763626
Webcast: A webcast of the live conference call can be accessed by visiting the Events section of the Company's website (click here) or directly (click here). An online replay will be available on the Company's website or via the direct link an hour after the call.
As previously announced, and formally approved by the Board of Directors, the Company is transitioning its fiscal year end from
About
About LungFit
LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders,
About Nitric Oxide
Nitric Oxide (NO) is a potent molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company's revenue guidance for calendar year 2026 and 2027; demand for, and hospital adoption of, the Company's LungFit PH systems, including the Company's pipeline, new account wins and renewals; the FDA's review of the Company's PMA supplement for the second-generation LungFit PH system, including the expected timing of completion of the Company's audit-readiness process and FDA inspections, and the potential approval, intended use, transport capability, commercial launch and commercial benefits of that system; the proposed NeuroNOS transaction, its consideration, closing conditions and anticipated benefits; development plans and resource allocation for LungFit GO; potential partnerships or other strategic arrangements for Beyond Cancer; the Company's liquidity, financing needs and ability to continue as a going concern; the Company's ability to scale its infrastructure; and the Company’s fiscal year-end transition and expected filing of a transition report on Form 10-K/T. Forward-looking statements may be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "potential," "will," "would," "could," "may," and similar expressions, or by the use of future tense. Because forward-looking statements relate to future events, they are subject to inherent risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the Company's ability to achieve its revenue guidance, which is based on assumptions regarding demand, hospital adoption, pricing, the timing of FDA approval of the second-generation LungFit PH system and other factors that may not be realized; whether the Company completes its audit-readiness process as anticipated; the timing and outcome of FDA inspections and whether the FDA approves the Company's PMA supplement for the second-generation LungFit PH system, including the requested transport labeling, which may not occur in a timely manner or at all; delays in the commercial launch of the second-generation LungFit PH system; the Company's reliance on third-party contract manufacturers; market acceptance of the Company's products and competition in the nitric oxide market; the possibility that the contemplated investment or other conditions to the NeuroNOS transaction are not satisfied, that the transaction does not close or its anticipated benefits are not realized, or that the value of the UNIVO securities is limited; the availability of resources for LungFit GO, the outcome of further clinical development and regulatory review; the Company's ability to secure and complete strategic arrangements for Beyond Cancer; the Company's history of losses and substantial doubt about its ability to continue as a going concern; the Company's ability to obtain the financing necessary to fund its operations and to satisfy its debt obligations as they come due, and the dilution that any equity financing may cause; the Company's ability to maintain the listing of its common stock on The Nasdaq Stock Market; and other risks described in the "Risk Factors" section of Beyond Air, Inc.'s most recent Annual Report on Form 10-K, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made and, except as required by law, the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contacts
Investor Relations contact
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577
CONSOLIDATED BALANCE SHEETS (in thousands) | ||||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 5,397 | $ | 6,740 | ||||
| Marketable securities | 5,652 | 4,901 | ||||||
| Restricted cash | 4,832 | 5,622 | ||||||
| Accounts receivable, net | 1,450 | 1,086 | ||||||
| Inventory, net | 1,190 | 1,406 | ||||||
| Other current assets and prepaid expenses | 5,083 | 5,012 | ||||||
| Current assets held for sale | 3,024 | - | ||||||
| Total current assets | 26,628 | 24,767 | ||||||
| Licensed right to use technology | 915 | 1,018 | ||||||
| Right-of-use lease assets | 1,003 | 1,193 | ||||||
| Property and equipment, net | 7,632 | 8,249 | ||||||
| Other assets | 77 | 158 | ||||||
| TOTAL ASSETS | $ | 36,255 | $ | 35,385 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 2,128 | $ | 2,417 | ||||
| Accrued expenses and other current liabilities | 4,094 | 3,372 | ||||||
| Operating lease liability, current portion | 211 | 321 | ||||||
| Loans payable, current portion | 58 | 401 | ||||||
| Current liabilities held for sale | 759 | - | ||||||
| Total current liabilities | 7,250 | 6,511 | ||||||
| Operating lease liability, net | 899 | 1,023 | ||||||
| Long-term debt, net | 21,982 | 21,639 | ||||||
| Warrant liability | - | 2 | ||||||
| Total liabilities | 30,131 | 29,175 | ||||||
| Stockholders’ equity | ||||||||
| Preferred Stock | - | - | ||||||
| Common Stock | - | - | ||||||
| (25 | ) | (25 | ) | |||||
| Additional paid-in capital | 340,604 | 325,588 | ||||||
| Accumulated deficit | (335,324 | ) | (319,571 | ) | ||||
| Accumulated other comprehensive income | 72 | 134 | ||||||
| Total stockholders’ equity attributable to | 5,327 | 6,126 | ||||||
| Non-controlling interest | 797 | 84 | ||||||
| Total stockholders’ equity | 6,124 | 6,210 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 36,255 | $ | 35,385 | ||||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) (UNAUDITED) | ||||||||||||||||
| For the Three Months Ended | For the Six Months Ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues | $ | 2,324 | $ | 1,818 | $ | 4,092 | $ | 3,578 | ||||||||
| Cost of revenues | 2,127 | 2,116 | 3,670 | 3,720 | ||||||||||||
| Gross profit (loss) | 197 | (298 | ) | 422 | (142 | ) | ||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 1,581 | 2,450 | 3,540 | 5,536 | ||||||||||||
| Selling, general, and administrative | 4,591 | 4,913 | 9,469 | 9,600 | ||||||||||||
| Total operating expenses | 6,172 | 7,363 | 13,009 | 15,136 | ||||||||||||
| Loss from operations | (5,975 | ) | (7,661 | ) | (12,587 | ) | (15,278 | ) | ||||||||
| Other income/(expense): | ||||||||||||||||
| Dividend/investment income | 93 | 59 | 196 | 87 | ||||||||||||
| Interest and finance expense | (1,504 | ) | (639 | ) | (2,996 | ) | (1,187 | ) | ||||||||
| Change in fair value of warrant liability | 1 | (1 | ) | 2 | 16 | |||||||||||
| Foreign exchange gain/(loss) | 29 | (18 | ) | 69 | (59 | ) | ||||||||||
| Loss on extinguishment of debt | (252 | ) | - | (405 | ) | - | ||||||||||
| Loss on disposal of fixed assets | - | (46 | ) | (52 | ) | (57 | ) | |||||||||
| Loss on contract manufacturer’s inventory obsolescence | (567 | ) | - | (567 | ) | - | ||||||||||
| Other income | - | 48 | 11 | 142 | ||||||||||||
| Total other expense | (2,200 | ) | (597 | ) | (3,742 | ) | (1,058 | ) | ||||||||
| Loss before income taxes | (8,175 | ) | (8,258 | ) | (16,329 | ) | (16,336 | ) | ||||||||
| Provision for income taxes | - | - | - | - | ||||||||||||
| Net loss | $ | (8,175 | ) | $ | (8,258 | ) | $ | (16,329 | ) | $ | (16,336 | ) | ||||
| Less: net loss attributable to non-controlling interest | (357 | ) | (318 | ) | (576 | ) | (705 | ) | ||||||||
| Net loss attributable to | $ | (7,818 | ) | $ | (7,940 | ) | $ | (15,753 | ) | $ | (15,631 | ) | ||||
| Other comprehensive income/(loss), net of tax | ||||||||||||||||
| Foreign currency translation adjustment | (41 | ) | 18 | (62 | ) | 145 | ||||||||||
| Comprehensive loss attributable to | $ | (7,859 | ) | $ | (7,922 | ) | $ | (15,815 | ) | $ | (15,486 | ) | ||||
| Net basic and diluted loss per share attributable to | $ | (3.76 | ) | $ | (24.98 | ) | $ | (11.22 | ) | $ | (54.95 | ) | ||||
| Weighted average number of shares of common stock outstanding, basic and diluted (1) | 2,078,853 | 317,829 | 1,403,780 | 284,471 | ||||||||||||
| Prior period results have been adjusted to reflect the one-for-twenty reverse stock split in |
Source: Beyond Air™